Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Vaccines01:30

Cancer Vaccines

936
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
936
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Brief Report on Global Clinician Practices in the First-Line Management of Metastatic Non-Small Cell Lung Cancer.

Clinical lung cancer·2024
Same author

Cancer Care in the Era of Artificial Intelligence.

JAMA oncology·2024
Same author

Frontline pembrolizumab monotherapy for metastatic non-small cell lung cancer with PD-L1 expression ≥50%: real-world outcomes in a US community oncology setting.

Frontiers in oncology·2024
Same author

Examining crossover and postprotocol therapies in first-line immunotherapy trials in non-small cell lung cancer.

Cancer·2024
Same author

Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review.

JAMA oncology·2023
Same author

ABIM Maintenance of Certification-Reply.

JAMA·2023

相关实验视频

Updated: Jan 11, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.1K

状非小细胞肺癌:当前和新兴的治疗选择

Paul K Paik1, Jianjun Zhang2, Howard Jack West3

  • 1Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Department of Medicine, Weill Cornell Medical College, New York, NY.

Clinical lung cancer
|November 18, 2025
PubMed
概括

与非状细胞肺癌相比,状非小细胞肺癌 (NSCLC) 的治疗选择有限. 本综述总结了状NSCLC的当前和新兴疗法,强调未满足的需求和未来的方向.

关键词:
ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI IC1 ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI ICI IC1 IC1 IC1 IC1 IC2 IC1 IC1 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 IC2 which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which which免疫治疗是一种免疫疗法.在NSCLCLC中,我们可以看到.在VEGF-A的基础上.有针对性的治疗.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

相关实验视频

Last Updated: Jan 11, 2026

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.1K
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.6K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.9K

科学领域:

  • 在瘤学瘤学.
  • 药理学 药理学是指药理学的学科.
  • 医学研究 医学研究

背景情况:

  • 非小细胞肺癌 (NSCLC) 的药理管理已取得进展,但在组织学亚型之间仍然存在治疗差异.
  • 某些疗法,如贝瓦西祖马布和佩米特雷克塞德,由于安全性或疗效方面的担忧,不适合状NSCLC.
  • 状NSCLC带来了独特的挑战,包括不同的突变格局和缺乏向治疗方法.

研究的目的:

  • 对状非小细胞肺癌 (NSCLC) 的现有和新兴治疗方案进行审查.
  • 突出状NSCLC治疗领域的局限性和未得到满足的需求.
  • 为这种特定的NSCLC亚型提供正在调查的药物治疗方法的全面概述.

主要方法:

  • 对状NSCLC当前和新兴药物疗法的文献综述.
  • 对治疗指南和临床试验数据的分析.
  • 综合有关治疗选择的信息,包括免疫疗法和化疗.

主要成果:

  • 免疫疗法,通常与化疗相结合,是状NSCLC在没有向疗法的情况下的主要治疗方法.
  • 状NSCLC患者的生存结果与非状NSCLC患者相比仍然较差.
  • 目前,一些有前途的药物疗法正在针对状NSCLC进行研究.

结论:

  • 在状与非状NSCLC的治疗选择中存在显著的差异.
  • 对于状NSCLC来说,急需新的向疗法和改进的治疗策略.
  • 目前正在进行的研究有望促进状NSCLC患者的护理.